Lennox-Gastaut Syndrome
- Health
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
Osaka, Japan & New York, United States: − Ovid eligible to receive up to $856M in payments, including a $196M…
Read More » - United States
Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome
Osaka, Japan & New York, United States: − Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared…
Read More »